Sanofi
SCTX

Sanofi’s Scribe Therapeutics Inc SCTX Stock Holding History

Sanofi’s Portfolio SCTX Stock Details SCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.2M Buy
+500,000
New +$13.2M 1.46% 14

Other funds holding SCTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Menlo Ventures Management
Menlo Ventures Management Menlo Park, California $241M AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Sanofi's SCTX Position: Q3 2026 in Review

Sanofi opened a new position in Scribe Therapeutics Inc (SCTX) in Q3 2026: 500,000 shares worth $9.2M. The stake represents 1.46% of the portfolio and ranks #14 among its holdings.

17 funds tracked by Wall St. Rank hold SCTX as of Q3 2026.

  • Sanofi held 500,000 shares of Scribe Therapeutics Inc worth $9.2M as of Q3 2026.
  • Scribe Therapeutics Inc was a new Sanofi position in Q3 2026.
  • Scribe Therapeutics Inc made up 1.46% of Sanofi's portfolio in Q3 2026, its #14 holding.
  • 17 funds tracked by Wall St. Rank held Scribe Therapeutics Inc as of Q3 2026.

Based on Sanofi's 13F filing for Q3 2026, filed 5 Nov 2026.